ArticleHua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology2020
[Clinical comment of programmed cell death protein 1 immunotherapy for advanced head and neck cancer].
Article in Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- Predicting response to immunotherapy in oral squamous cell carcinoma via a CT-based radiomics model.BMC medical imaging · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-programmed cell death protein 1 (PD-1) monoclonal antibody is a landmark drug in the field of malignant tumor treatment, and its emergence has resulted in the use of immunotherapy in treating various types of malignancies. A large number of clinical studies abroad have shown that it has a more significant effect than traditional strategies in the treatment of advanced head and neck cancer, and it has a significantly lower incidence of adverse events than chemotherapy. Recently, the clinical application of anti-PD-1 monoclonal antibodies in China has changed the traditional treatment mode of head and neck malignant tumors. Immunotherapy has become the first-line treatment option for recurrent/metastatic head and neck cancer. Furthermore, the indications of PD-1 monoclonal antibodies have been continuously expanded through clinical trials, and their biomarkers have been explored and validated. The application of PD-1 monoclonal antibodies tend to be individualized and precise and potentially improves the treatment levels of advanced head and neck malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.